C9

Complement component C9 · P02748 · C9 on Sugi Atlas →

87 patent compounds predicted against C9, 69 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Aurintricarboxylic Acid (SCHEMBL98495)	1.00	3/20
SCHEMBL14673324	1.00	3/20
Aurintricarboxylic Acid (SCHEMBL29353681)	1.00	3/20
Aurintricarboxylic Acid (SCHEMBL29450069)	1.00	3/20
Aurintricarboxylic Acid (SCHEMBL515038)	0.97	3/20
Aurintricarboxylic Acid (SCHEMBL4644958)	0.97	3/20
Aurintricarboxylic Acid (SCHEMBL6158321)	0.97	3/20
Aurintricarboxylic Acid (SCHEMBL10791075)	0.97	3/20
Aurintricarboxylic Acid (SCHEMBL15874321)	0.97	3/20
Aurintricarboxylic Acid (SCHEMBL29395768)	0.97	3/20
Aurintricarboxylic Acid (SCHEMBL30831678)	0.97	3/20
Aurintricarboxylic Acid (SCHEMBL6847597)	0.95	3/20
SCHEMBL13161169	0.88	3/20
Aurintricarboxylic Acid (SCHEMBL7931573)	0.81	3/20
SCHEMBL9755148	0.80	3/20
SCHEMBL14269440	0.80	3/20
SCHEMBL25438838	0.79	3/20
SCHEMBL10028458	0.77	3/20
SCHEMBL12634308	0.76	3/20
SCHEMBL4918769	0.74	3/20

Clinical trials — most relevant to C9 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS	PHASE4	COMPLETED
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation	PHASE3	COMPLETED
The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children	PHASE3	UNKNOWN
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment	PHASE3	COMPLETED
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema	PHASE3	COMPLETED
A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC GENERIUM, Russian Federation)	PHASE3	COMPLETED
Ravulizumab and COVID-19	PHASE3	UNKNOWN
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis	PHASE2	COMPLETED
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab	PHASE2	WITHDRAWN
Complement C5 mAb in the Treatment of Anti-GBM Disease	PHASE2	COMPLETED
Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease	PHASE2	COMPLETED
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation	PHASE1	COMPLETED
TP10 Use in Patients With C3 Glomerulopathy (C3G)	PHASE1	WITHDRAWN
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy	PHASE1	COMPLETED
Complement Activation in the Lysosomal Storage Disorders	nan	WITHDRAWN
Effect of Platelet Storage on Complement Activation	nan	UNKNOWN
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)	nan	RECRUITING
Procedure Outcome Predictor (POP) Using the Complement Cascade	nan	COMPLETED
Perioperative Salivary Alpha-amylase as a Predictor of Delirium After Lower Extremity Vascular Bypass Surgery	nan	COMPLETED
Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome	nan	COMPLETED
Amyotrophic Lateral Sclerosis and the Innate Immune System	nan	RECRUITING
Complement C5a Receptors in Hidradenitis Suppurativa	nan	COMPLETED
Assessment of Whole Blood Cold Stored Platelets	nan	COMPLETED
New Analytic Tools for aHUS and C3G Diagnosis	nan	ACTIVE_NOT_RECRUITING
Transcriptome and Metabolic Analyses of CHAPLE Disease	nan	UNKNOWN
Role of Renal Artery Doppler in Critically Ill Children With Acute Kidney Injury	nan	UNKNOWN
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry	nan	RECRUITING
Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis	nan	COMPLETED
TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis	nan	UNKNOWN
Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a C9 binder may also engage these)

Protein	Name	Similarity
Q3MHN2	—	1.000	Q3MHN2 →
P48770	—	1.000	P48770 →
P06683	—	1.000	P06683 →
Q62930	—	1.000	Q62930 →
P55314	—	0.994	P55314 →
Q8BH35	—	0.994	Q8BH35 →
P06682	—	0.994	P06682 →
P07357	—	0.993	P07357 →
P48747	—	0.993	P48747 →
P13671	—	0.992	P13671 →
Q5RAD0	—	0.992	Q5RAD0 →
Q29RU4	—	0.992	Q29RU4 →
P61134	—	0.992	P61134 →
E9Q6D8	—	0.991	E9Q6D8 →
P10643	—	0.990	P10643 →
Q8K182	—	0.990	Q8K182 →
P79755	—	0.989	P79755 →
Q9PVW7	—	0.988	Q9PVW7 →
P61135	—	0.988	P61135 →
P98136	—	0.987	P98136 →
Q90X85	—	0.987	Q90X85 →
P98137	—	0.986	P98137 →
D3YXF5	—	0.986	D3YXF5 →
Q29RQ1	—	0.985	Q29RQ1 →
Q811M5	—	0.985	Q811M5 →
Q66K08	—	0.985	Q66K08 →
Q9TUQ3	—	0.985	Q9TUQ3 →
P07358	—	0.984	P07358 →
O75339	—	0.983	O75339 →
B4HVU2	—	0.982	B4HVU2 →